Swiss Pharma Nycomed Agrees To Market NPS’ Gattex Ex-U.S.
This article was originally published in The Pink Sheet Daily
NPS gets $35 million upfront, potential $150 million in milestones and double-digit royalties from Nycomed for Gattex.
You may also be interested in...
Clinical data for teduglutide, which goes before the Gastrointestinal Drugs Advisory Committee Oct. 16 as the first drug for treating short bowel syndrome, includes positive results from a confirmatory trial and mixed results from the initial study.
The EU's CHMP gave positive opinions on three new products – Novartis' glycopyrronium, AstraZeneca's ceftaroline and Takeda's teduglutide – and on a major new indication for Novartis’ everolimus (Afinitor), after its meeting on June 18-21.
Short-bowel syndrome candidate demonstrates long-term safety and tolerability, meets efficacy endpoints.